Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…
MaaT PharmaOctober 7, 2022
MaaT Pharma Publishes its Half Year Results and Provides a Business Overview For the first…
MaaT PharmaSeptember 29, 2022
MaaT Pharma Announces Participation in Three Upcoming Investor Conferences in September Lyon, France, September 8th,…
MaaT PharmaSeptember 8, 2022
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…
MaaT PharmaSeptember 6, 2022
MaaT Pharma Announces Update on U.S. FDA Investigational New Drug Application for MaaT013 in Patients…
MaaT PharmaAugust 10, 2022
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…
MaaT PharmaAugust 1, 2022
MaaT Pharma Reports Cash and Revenues for Second Quarter 2022 As of June 30, 2022,…
MaaT PharmaJuly 28, 2022
MaaT Pharma Announces the Availability of the 2021 Universal Registration Document Lyon, France, July 6,…
MaaT PharmaJuly 6, 2022
MaaT Pharma Confirms Positive Results from Completed Phase 1b CIMON Study Evaluating MaaT033 in Blood…
MaaT PharmaJune 2, 2022
